secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001213900-25-116307
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics appoints Dr. Lee Golden to Board of Directors
-------------------------------------------------------------------

- Dr. Lee Scott Golden appointed independent Class II director effective Nov 24, 2025; term expires at 2027 annual meeting.
- Golden is EVP and CMO of PTC Therapeutics (PTCT) with 25+ years in cardiovascular and hematologic drug development.
- Golden serves on Science and Technology Committee; receives $35,000 annual fee plus equity awards.
- Appointment aligns with Cadrenal's focus on advancing tecarfarin for anticoagulation unmet needs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025116307/0001213900-25-116307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025116307/ea0267189-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-116307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer